Bank of New York Mellon’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-75,422
| Closed | -$123K | – | 4202 |
|
|
2025
Q1 | $123K | Buy |
75,422
+13,784
| +22% | +$27.7K | ﹤0.01% | 3974 |
|
|
2024
Q4 | $113K | Buy |
61,638
+425
| +0.7% | +$1.88K | ﹤0.01% | 4022 |
|
|
2024
Q3 | $354K | Sell |
61,213
-20,622
| -25% | -$170K | ﹤0.01% | 3680 |
|
|
2024
Q2 | $661K | Buy |
+81,835
| New | +$861K | ﹤0.01% | 3421 |
|
|
2024
Q1 | – | Sell |
-10,924
| Closed | -$66.9K | – | 4237 |
|
|
2023
Q4 | $66.9K | Hold |
10,924
| – | – | ﹤0.01% | 4138 |
|
|
2023
Q3 | $51K | Sell |
10,924
-147
| -1% | -$812 | ﹤0.01% | 4161 |
|
|
2023
Q2 | $59.3K | Sell |
11,071
-61,808
| -85% | -$498K | ﹤0.01% | 4153 |
|
|
2023
Q1 | $717K | Sell |
72,879
-1,499
| -2% | -$25.6K | ﹤0.01% | 3295 |
|
|
2022
Q4 | $1.39M | Buy |
74,378
+148
| +0.2% | +$3.35K | ﹤0.01% | 3039 |
|
|
2022
Q3 | $1.54M | Buy |
74,230
+13,930
| +23% | +$357K | ﹤0.01% | 2994 |
|
|
2022
Q2 | $1.25M | Sell |
60,300
-4,735
| -7% | -$133K | ﹤0.01% | 3100 |
|
|
2022
Q1 | $2.8M | Sell |
65,035
-268
| -0.4% | -$12.1K | ﹤0.01% | 2744 |
|
|
2021
Q4 | $3.91M | Sell |
65,303
-6,792
| -9% | -$544K | ﹤0.01% | 2600 |
|
|
2021
Q3 | $6.19M | Sell |
72,095
-4,473
| -6% | -$449K | ﹤0.01% | 2381 |
|
|
2021
Q2 | $8.52M | Buy |
76,568
+16,920
| +28% | +$1.63M | ﹤0.01% | 2233 |
|
|
2021
Q1 | $6.64M | Buy |
59,648
+5,873
| +11% | +$772K | ﹤0.01% | 2312 |
|
|
2020
Q4 | $5.71M | Buy |
53,775
+2,668
| +5% | +$355K | ﹤0.01% | 2302 |
|
|
2020
Q3 | $7.11M | Buy |
51,107
+640
| +1% | +$133K | ﹤0.01% | 2041 |
|
|
2020
Q2 | $16.3M | Buy |
50,467
+22,400
| +80% | +$3.6M | ﹤0.01% | 1569 |
|
|
2020
Q1 | $2.51M | Buy |
28,067
+3,116
| +12% | +$192K | ﹤0.01% | 2441 |
|
|
2019
Q4 | $988K | Sell |
24,951
-6,265
| -20% | -$189K | ﹤0.01% | 3252 |
|
|
2019
Q3 | $767K | Sell |
31,216
-1,209
| -4% | -$36.8K | ﹤0.01% | 3312 |
|
|
2019
Q2 | $1.14M | Buy |
32,425
+1,349
| +4% | +$53.6K | ﹤0.01% | 3120 |
|
|
2019
Q1 | $1.39M | Buy |
31,076
+1,007
| +3% | +$50.8K | ﹤0.01% | 2975 |
|
|
2018
Q4 | $1.44M | Buy |
30,069
+1,109
| +4% | +$67.4K | ﹤0.01% | 2900 |
|
|
2018
Q3 | $1.93M | Buy |
28,960
+560
| +2% | +$31.2K | ﹤0.01% | 2847 |
|
|
2018
Q2 | $1.33M | Sell |
28,400
-2,520
| -8% | -$139K | ﹤0.01% | 3087 |
|
|
2018
Q1 | $1.75M | Buy |
30,920
+1,192
| +4% | +$64.5K | ﹤0.01% | 2885 |
|
|
2017
Q4 | $1.47M | Sell |
29,728
-2,123
| -7% | -$132K | ﹤0.01% | 3019 |
|
|
2017
Q3 | $2.42M | Buy |
31,851
+4,719
| +17% | +$351K | ﹤0.01% | 2727 |
|
|
2017
Q2 | $2.55M | Sell |
27,132
-1,397
| -5% | -$119K | ﹤0.01% | 2705 |
|
|
2017
Q1 | $2.27M | Buy |
28,529
+980
| +4% | +$78.1K | ﹤0.01% | 2782 |
|
|
2016
Q4 | $2.29M | Buy |
27,549
+926
| +3% | +$83.7K | ﹤0.01% | 2770 |
|
|
2016
Q3 | $2.98M | Sell |
26,623
-1,677
| -6% | -$185K | ﹤0.01% | 2525 |
|
|
2016
Q2 | $3.14M | Sell |
28,300
-227
| -0.8% | -$27.6K | ﹤0.01% | 2461 |
|
|
2016
Q1 | $2.98M | Buy |
28,527
+1,090
| +4% | +$84.2K | ﹤0.01% | 2436 |
|
|
2015
Q4 | $2.21M | Sell |
27,437
-2,438
| -8% | -$194K | ﹤0.01% | 2652 |
|
|
2015
Q3 | $2.07M | Sell |
29,875
-6,026
| -17% | -$525K | ﹤0.01% | 2721 |
|
|
2015
Q2 | $3.52M | Buy |
35,901
+9,778
| +37% | +$1.04M | ﹤0.01% | 2569 |
|
|
2015
Q1 | $2.56M | Sell |
26,123
-313
| -1% | -$30.3K | ﹤0.01% | 2690 |
|
|
2014
Q4 | $2.91M | Buy |
26,436
+3,661
| +16% | +$447K | ﹤0.01% | 2613 |
|
|
2014
Q3 | $2.69M | Buy |
22,775
+709
| +3% | +$88.3K | ﹤0.01% | 2670 |
|
|
2014
Q2 | $2.86M | Buy |
22,066
+17,042
| +339% | +$2.01M | ﹤0.01% | 2682 |
|
|
2014
Q1 | $803K | Buy |
5,024
+426
| +9% | +$61.1K | ﹤0.01% | 3390 |
|
|
2013
Q4 | $640K | Sell |
4,598
-1,537
| -25% | -$154K | ﹤0.01% | 3491 |
|
|
2013
Q3 | $610K | Buy |
6,135
+5,018
| +449% | +$421K | ﹤0.01% | 3446 |
|
|
2013
Q2 | $43K | Buy |
+1,117
| New | +$33.9K | ﹤0.01% | 4052 |
|
Other funds holding INO
DTC
Bank of New York Mellon's INO Position: Q2 2025 in Review
Bank of New York Mellon sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 75,422 shares — an estimated $123K sold.
Bank of New York Mellon first reported a position in INO in Q2 2013 and held it in 47 quarters. The position peaked at $16.3M in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.
- Bank of New York Mellon reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Bank of New York Mellon sold 75,422 Inovio Pharmaceuticals shares in Q2 2025, an estimated $123K.
- Bank of New York Mellon first reported a position in Inovio Pharmaceuticals in Q2 2013 and held it in 47 quarters.
- Bank of New York Mellon's Inovio Pharmaceuticals position peaked at $16.3M in Q2 2020.
- 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.
Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.